FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.
Adam C. Fisher, PhD
Advertisement
Director of Science Staff, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA
Articles by Adam C. Fisher, PhD
Advertisement
Latest Updated Articles
The Manufacturing Edge on Path to MarketPublished: September 9th 2022 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Bob Mauch: Strengthening the Chain
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
